BioCryst Pharmaceuticals, Inc. (BCRX) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.70 +3.20%
EPS Growth %: -43.8%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -43.8%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $8.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
- LuxExperience B.V. (LUXE) Misses Q2 EPS by 11c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
